Febrile seizures in children older than 3 years require prompt, structured management. This protocol targets the specific age group of children above 3 years, where distinct approved therapeutic options apply.
A child aged above 3 years presenting with a febrile seizure. Age-specific guidance is established for this group, with recognised treatment options defined for children in this age range.
The primary objective is termination of the febrile seizure — achieving seizure cessation as quickly as possible.
When intravenous access is available, an intravenous benzodiazepine forms the basis of intervention. The complete protocol — covering agent selection, sequencing, and all relevant clinical considerations — is available in the full structured regimen.
DOI: 10.1186/s13052-024-01666-1
In Italy, buccal MDZ has received approval for the treatment of prolonged febrile seizures in children aged above three years and should be administered at a dose of 0.5 mg/kg with pre-dosed syringes formulations (3–4 years: 5 mg; 5–9 years: 7.5 mg; 10–18 years: 10 mg).
If intravenous access is available, other BDZs could be considered.
View source ↗